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Abstract
Background: Periostin is a biomarker indicating the presence of type 2 inflammation and submucosal fibrosis;
serum periostin levels have been associated with asthma severity. Macrolides have immunomodulatory effects
and are considered a potential therapy for patients with severe asthma. Therefore, we investigated whether
macrolides can also modulate pulmonary periostin production.
Methods: Using quantitative PCR and ELISA, we measured periostin production in human lung fibroblasts stimulated
by interleukin-13 (IL-13) in the presence of two 14-member–ring macrolides—clarithromycin or erythromycin—or a
16-member–ring macrolide, josamycin. Phosphorylation of signal transducers and activators of transcription 6 (STAT6),
downstream of IL-13 signaling, was evaluated by Western blotting. Changes in global gene expression profile induced
by IL-13 and/or clarithromycin were assessed by DNA microarray analysis.
Results: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13–stimulated periostin production.
The inhibitory effects of clarithromycin were stronger than those of erythromycin. Clarithromycin significantly
attenuated STAT6 phosphorylation induced by IL-13. Global gene expression analyses demonstrated that IL-13
increased mRNA expression of 454 genes more than 4-fold, while decreasing its expression in 390 of these
genes (85.9%), mainly “extracellular,” “plasma membrane,” or “defense response” genes. On the other hand,
clarithromycin suppressed 9.8% of the genes in the absence of IL-13. Clarithromycin primarily attenuated the
gene expression of extracellular matrix protein, including periostin, especially after IL-13.
Conclusions: Clarithromycin suppressed IL-13–induced periostin production in human lung fibroblasts, in part
by inhibiting STAT6 phosphorylation. This suggests a novel mechanism of the immunomodulatory effect of
clarithromycin in asthmatic airway inflammation and fibrosis.
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Background
The immunomodulatory effects of macrolides were first
described in patients with diffuse panbronchiolitis in
1998 [1]. Macrolide immunomodulation was found to be
independent of antibiotic properties [2]. Their effects
include modulation (both increasing and decreasing) of
inflammatory cytokine production, decreasing airway
mucus hypersecretion, and blocking bacterial biofilm
formation and virulence factor production [2–5]. Macro-
lide therapy has been recommended for chronic ob-
structive pulmonary disease, cystic fibrosis, non-cystic
fibrosis bronchiectasis, and severe asthma [6–10]. In
patients with asthma, long-term macrolide therapy was
reported to improve airflow, quality of life, and airway
hypersensitiveness [11].
Periostin is an extracellular matrix protein that is as-
sociated with eosinophilic airway inflammation and the
severity of asthma. Periostin may enhance type 2
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inflammation and mucus hypersecretion [12–15]. Peri-
ostin is reported to be the most robust biomarker pre-
dicting the effectiveness of lebrikizumab, an anti-IL-13
antibody, for treating asthma [16–18]. As macrolides
also affect type 2-dominated inflammation in asthma,
we hypothesized that macrolide therapy may attenuate
IL-13 stimulated periostin production and inflamma-
tory gene expression in human lung fibroblasts.
Methods
Cell culture
MRC5 cells, a human embryonic lung fibroblast cell line
(Riken BioResource Center, Tsukuba, Japan), were cul-
tured with Dulbecco modified Eagle medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10%
fetal calf serum, 100 μg/mL streptomycin, and 100 U/mL
penicillin G. MRC5 cells (7 × 104 cells per well) were
placed in 24-well plates (Nunc, Roskilde, Denmark) and
cultured in 5% CO2 humidified atmosphere at 37 °C with
or without clarithromycin, erythromycin (Wako Pure
Chemical Industries, Osaka, Japan), josamycin (Sigma-
Aldrich), ampicillin (Sigma-Aldrich), or dexamethasone
(Wako Pure Chemical Industries). Clarithromycin was
kindly supplied by Taisho Toyama Co., Ltd. (Tokyo,
Japan). Clarithromycin, erythromycin, josamycin, and
ampicillin were dissolved in ethanol (EtOH, Wako) to
therapeutic concentrations [19, 20]. Dexamethasone
was dissolved in EtOH to 100 nM [21]. The final con-
centration of EtOH added to cells was 0.5%. After 24 h
of culture, cells were stimulated by 50 ng/mL human
recombinant IL-13 (Peprotech, Rocky Hill, NJ, USA)
for 24 h. Cell viability was evaluated using WST-8 assay
(Cell Count Reagent SF, Nacalai Tesque, Kyoto, Japan).
Real-time PCR
Total RNA was extracted using RNAiso Plus (Takara
Bio, Otsu, Japan), and reverse-transcribed with Rever-
Tra Ace (Toyobo, Osaka, Japan). Quantitative PCR re-
actions were performed with cDNA on a StepOnePlus
real-time PCR System (Life Technologies, Carlsbad,
CA, USA) using the Thunderbird SYBR qPCR mix
(Toyobo). PCR primers were as follows: periostin, for-
ward primer, 5’-CTGCCAAACAAGTTATTGAGCTG
GC-3’, reverse primer, 5’-AATAATGTCCAGTCTCC
AGGTTG-3’ and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), forward primer, 5’-TCACCACCAT
GGAGAAGGC-3’, reverse primer, 5’-GCTAAGCAG
TTGGTGGTGCA-3’. Threshold cycles of primer
probes were normalized by GAPDH Additional file 1.
ELISA
Periostin ELISA was performed using Periostin ELISA
Kit® (Shino-Test Corp., Tokyo, Japan) according to the
manufacturer's instruction.
Western blot analysis
Western blotting for STAT6 and phosphorylated STAT6
was performed as previously described [22]. MRC5 cells
were stimulated with the indicated concentration of IL-
13 at 37 °C for 1, 3, or 6 h. The cell lysates were applied
to SDS-PAGE and then electrophoretically transferred to
polyvinylidene difluoride membranes. Membranes were
incubated with either anti-phosphotyrosyl STAT6 anti-
body (Cell Signaling Technology, Beverly, MA, USA) or
anti-STAT6 Ab (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), followed by incubation with secondary Abs
conjugated to horseradish peroxidase. The signals were
visualized with an enhanced chemiluminescence system
(Thermo Scientific, Waltham, MA, USA) and LAS-3000
(GE Healthcare, Pittsburg, PA, USA).
DNA microarray analysis
MRC5 cells were stimulated with 50 ng/mL IL-13 for
24 h in the presence or absence of 5.0 × 10−5 M clari-
thromycin to evaluate not only the primary gene tran-
scription but also the secondary gene expression caused
by the primary products. Total RNA with an RNA integ-
rity number more than 7.0 was applied to Agilent
Expression Array (SurePrint G3 Human GE8x60K v2
Microarray, Takara Bio). The calculated relative signal
intensity values were presented on a heat map and sub-
jected to MultiExperiment Viewer (MeV) v4.9 software
(Dana-Farber Cancer Institute, Boston, MA, USA). For
gene ontology analysis, the Database for Annotation
Visualization and Integrated Discovery (DAVID) tool
(National Cancer Institute, Frederick, MA, USA) was
used. This database includes the Gene Ontology Data-
base (http://geneontology.org/).
Statistical analysis
Statistical analyses were performed using the Prism 5.0
software (GraphPad Software, La Jolla, CA, USA) and
the IBM SPSS statistics 21.0 software package (IBM
SPSS, Tokyo, Japan). Data were presented as mean ± SD.
The significance of differences was assessed using an un-
paired Student’s t-test, except for the multiple compari-
sons of compounds, which were done using the ANOVA
plus post-test (Tukey). P values less than 0.05 were con-
sidered statistically significant.
Results
Clarithromycin inhibits periostin production in MRC5 cells
We first examined whether clarithromycin affects IL-13–
stimulated periostin production. We chose the concentra-
tions of clarithromycin based on an earlier reference
showing the clarithromycin concentration in epithelial
lining fluid after taking clarithromycin [19]. IL-13 in-
creased periostin expression approximately 10-fold
compared to control as reported previously [22] (Fig. 1).
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Clarithromycin significantly attenuated IL-13 stimu-
lated periostin in a dose-dependent manner from 318 ±
19 ng/mL with no clarithromycin to 168 ± 18 ng/mL (at
5.0 × 10−5 M, P < 0.001). Cellular viability was not af-
fected by clarithromycin at these concentrations (data
not shown). These results suggest that clarithromycin
inhibits periostin production in a dose-dependent man-
ner in human fibroblasts.
Effects of macrolides, dexamethasone, and ampicillin on
periostin production
The immunomodulatory effects of macrolides have been
reported to be associated with the size of the macrolactam
ring; macrolides with 14- or 15-member rings exhibit
immunomodulatory properties, while these properties
are absent or attenuated in the 16-member–ring
macrolide antibiotics [2]. Clarithromycin, like erythro-
mycin, is a 14-member–ring macrolide, while josamy-
cin, has a 16-member ring. Clarithromycin robustly
inhibited periostin production at both 2.5 × 10−5 M (P
< 0.01) and 5.0 × 10−5 M (P < 0.001) (Fig. 2). Erythro-
mycin inhibited IL-13–stimulated periostin production
more weakly than clarithromycin but significantly at
5.0 × 10−5 M (P < 0.01). However, josamycin had no effect
on periostin production (P = 0.3020), nor did ampicillin
(P = 0.6052). Dexamethasone, at a concentration of 10−7
M, also attenuated periostin production (P < 0.001). These
results suggest that clarithromycin and erythromycin, both
having 14-member rings, but not josamycin, with 16-
member ring, inhibit periostin production induced by IL-
13 in human lung fibroblasts.
Clarithromycin inhibits IL-13–induced STAT6
phosphorylation
IL-13 receptor activation signals through STAT6 phos-
phorylation [23]. Tanabe et al. reported that clarithromy-
cin inhibits STAT6 phosphorylation in human bronchial
epithelial cells [20]. We hypothesized that STAT6 in-
hibition by clarithromycin would decrease IL-13–stimu-
lated periostin expression in MRC5 fibroblasts. IL-13
induced STAT6 phosphorylation within 1 h, and this con-
tinued for more than 6 h (Fig. 3). Clarithromycin partially
attenuated STAT6 phosphorylation just 1 h after IL-13
exposure. These results suggest that clarithromycin atten-
uates periostin production induced by IL-13 at least par-
tially by inhibiting STAT6 phosphorylation.
IL-13 and clarithromycin affect gene expression in
MRC5 cells
To examine the selectivity of the inhibitory effects by
clarithromycin on IL-13–induced expression, we analyzed
the changes in IL-13– and clarithromycin-dependent gene
expression. Global gene expression analysis showed that
IL-13 increased mRNA expression of 454 genes more than
4-fold. Of these 454 genes, clarithromycin exposure
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Fig. 1 Effects of clarithromycin on periostin production in MRC5 cells.
Periostin protein in supernatant measured by ELISA (a) or mRNA
by qPCR (b). Bars are depicted as mean ± SD. The same experiments
were performed twice for (A) and three times for (B). A representative
result of three individual experiments is shown. *; P < 0.05 compared
with IL-13 (50 ng/mL) plus EtOH (0.5%)
Fig. 2 Effects of erythromycin, josamycin, and ampicillin on periostin
production in MRC5 cells. MRC5 cells were cultured for 24 h in the
presence of the indicated concentrations of dexamethasone,
clarithromycin, erythromycin, josamycin, or ampicillin. Then the cells
were stimulated with 50 ng/mL IL-13 for 24 h. Periostin protein in
supernatant was measured by ELISA. The same experiments were
performed twice. Bars are depicted as mean ± SD. A representative
result of three individual experiments is shown. *; P < 0.05 compared
with IL-13 (50 ng/mL) plus EtOH (0.5%)
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attenuated expression of 390 (85.9%, Fig. 4a). The Gene
Ontology (GO) terminology provides uniform and con-
sistent descriptions of genes and gene products (http://
geneontology.org/). We categorized the genes affected
by IL-13 and clarithromycin using GO terminology. IL-13
primarily increased mRNA in “extracellular,” “plasma
membrane,” or “defense response” genes, whereas clari-
thromycin suppressed these categories of genes, but had
no effect on “negative regulation of cell communication,”
“glycoprotein,” or “Golgi apparatus” genes (Fig. 4b and
Table 1). In GO terminology, periostin belongs to an
extracellular region gene. In the absence of IL-13 stimula-
tion, clarithromycin suppressed 5758 of 58718 genes
(9.8%). The genes categorized as “extracellular region,”
“plasma membrane,” or “defense response,” which were
suppressed by clarithromycin in the presence of IL-13,
were only partially attenuated in the absence of IL-13: 9 of
56 genes (16.1%), 8 of 93 genes (8.6%), and 2 of 16 genes
(12.5%), respectively. These findings suggest that clarithro-
mycin inhibits mainly “extracellular,” “plasma membrane,”
or “defense response” genes induced by IL-13 in which
periostin is involved.
Discussion
It has been consistently reported that macrolides with
14- and 15-member rings have much greater immuno-
modulatory effects than the 16-member ring macrolides
[2]. In this study, we showed that clarithromycin, a 14-
member–ring macrolide, showed the strongest inhibitory
effects on periostin expression induced by IL-13 among
the examined macrolides. Erythromycin, another 14-
member–ring macrolide, showed fewer inhibitory effects
while josamycin, a 16-member–ring macrolide, had no
such effects. The details of what causes these differences
in the inhibitory effects are thus far unclear; however,
our results are consistent with these reports in that clari-
thromycin had the greatest suppressive effect on IL-13–
induced periostin expression [2].
The Janus kinase (JAK)-STAT6 pathway is key to IL-
13 signaling [24]. We confirmed that clarithromycin
suppressed the phosphorylation of STAT6, but the abil-
ity of clarithromycin to attenuate periostin production
may not entirely be explained by inhibiting STAT6
phosphorylation. There are several reports that STAT6
inhibition stops most periostin expression in lung fibro-
blasts [25]. These data indicate that STAT6 is the exclu-
sive regulator of periostin expression in lung fibroblasts.
On the other hand, we have recently demonstrated that
the periostin level is decreased in bronchial epithelial cells
by inhibitors against extracellular signal-regulated kinase
(ERK) and nuclear factor-kappa B (NF-κB) in addition to
STAT6, suggesting that in other cell types, the ERK and
NF-κB pathways are involved in periostin production [26].
Additionally, it has been reported that the ERK signaling
pathway positively regulates JAK1/STAT6 activity in T
cells [27]. On the other hand, macrolides are known to
decrease ERK and NF-κB signaling pathways [28].
Tanabe et al. reported that clarithromycin attenuates
these pathways and the JAK-STAT6 pathway [20].
Taken together, these results suggest that macrolides
may attenuate periostin production via the ERK or NF-
κB signaling pathways in addition to the JAK/STAT6
pathway. Clarithromycin may affect STAT6 signaling by
downregulating IL-13Rα1/IL-4Rα. We performed flow
cytometry to investigate the surface expression of the
cytokine receptors on MRC5 cells upon treatment with
clarithromycin (Additional file 2: Figure S1A). The
expression of IL-13Rα1 was not affected by clarithro-
mycin. Although a statistically significant decrease of
IL-4Rα expression was observed, it seemed too slight to
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Fig. 3 Clarithromycin inhibits IL-13–stimulated STAT6 phosphorylation. MRC5 cells were stimulated by exposure to 50 ng/mL IL-13 in the presence or
absence of clarithromycin. Phosphorylated STAT6 in the cell lysates of MRC5 cells was analyzed by Western blot. Bars are depicted as mean ± SD. The
same experiments were performed three times; a representative result of three individual experiments is shown. **; P < 0.001 compared with
control, #; P < 0.05, ##; P < 0.001 compared with no clarithromycin, NS; not significant
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explain the considerable attenuation of the periostin
production by clarithromycin. To confirm the expres-
sion of these receptors at the transcriptional level, we
also performed quantitative PCR, finding no suppres-
sive effect by clarithromycin (Additional file 2: Figure
S1B). Consequently, we conclude that the inhibition of
the STAT6 signaling by clarithromycin is not mainly due
to downregulation of the IL-13Rα1/IL-4Rα expression.
We found that clarithromycin showed significantly
suppressive effects on IL-13–inducble genes (Fig. 4).
These specific genes, whose expression was attenuated
by clarithromycin after IL-13 exposure, were dominantly
categorized as “extracellular region,” “plasma mem-
brane,” and “defense response” genes, among which
asthma-related CD40, NOS2, and CXCL1 (Table 1A)
were included. The improvement of asthma symptoms
by clarithromycin may be attributed to the downregula-
tion of these genes in addition to periostin. In contrast to
suppression of genes activated by IL-13, constitutive ex-
pression of these genes was less affected by clarithromycin.
Macrolides are classified as ‘immunomodulators’ and de-
crease hyperinflammation without impairing the normal
immune system against infection, as differentiated from
immunosuppressive agents such as glucocorticosteroids
[2]. The detailed mechanism of how macrolides select for
suppressive genes still remains unclear; however, our
present finding that clarithromycin selectively suppresses
IL-13–inducible genes including periostin may shed light
on this mechanism. Extracellular matrix proteins consti-
tute a positive feedback loop in lung fibrosis [23, 29].
Masuoka et al. showed that type 2 cytokines stimulated
fibroblasts to produce periostin, interacting with αv integ-
rin, a functional periostin receptor, on keratinocytes [23].
Inhibition of periostin or αv integrin prevented the devel-
opment or progression of allergen-induced skin inflamma-
tions, including fibrosis. Macrolides are reported to have
anti-fibrotic effects [30], implying that they may attenuate
fibrosis by modulating extracellular matrix proteins.
Serum periostin levels are significantly increased in asth-
matic patients [12]. The role of periostin on fibrogenesis
Fig. 4 Global gene expression analysis. a A hierarchical clustering using DNA microarray analysis of IL-13– and clarithromycin-dependent gene
expression changes in MRC5 cells. Genes whose expression were increased more than 4-fold by IL-13 without clarithromycin are displayed. The
rows represent genes; the experimental conditions are shown as columns. The color represents the expression level of the gene (Red represents
high expression, while green represents low expression). The dendrograms provide some qualitative means of assessing the similarity between
genes and between experimental conditions. Among IL-13–inducible genes, expression of 390 genes was decreased by 50% or more, 56 genes
were unaffected (0.5 to 1.5-fold), and expression of 8 genes was further increased by clarithromycin. b GO term decreased (a) or unchanged (b)
by clarithromycin among genes increased 4-fold by IL-13. Gene enrichment in each GO term was analyzed by Fisher’s exact test. P values for (a)
are extracellular region, 6.9E-04; plasma membrane, 1.6E-04; defense response, 6.1E-04; epidermis development, 1.3E-03; TNFR, 2.3E-02; positive
regulation of immune system process, 4.5E-03; positive regulation of multicellular organismal process; 5.1E-03; and regulation of protein kinase
cascade, 5.6E-03. P values for (b) are negative regulation of cell communication, 9.4E-03; glycoprotein, 5.6E-03; Golgi apparatus part, 2.1E-02;
chemotaxis, 4.0E-02; signal, 7.0E-02; and regulation of phosphorylation, 2.4E-01
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has been explored, showing that epithelial cell-derived
periostin increased secretion of type 1 collagen from air-
way fibroblasts [14]. Attenuation of periostin production
by macrolides may decrease both asthmatic airway inflam-
mation and fibrosis.
This study has a certain limitation. We selected the
concentration of clarithromycin (5.0 × 10−5 M) based on
a previous report showing the clarithromycin concentra-
tion in epithelial lining fluid after taking clarithromycin
[19]. Our study and most of the studies assessing the
effects of macrolides used the unified concentrations
for each drug when comparing the immunomodulatory
effects among macrolides with different types of rings
[4, 5]. We did not evaluate whether these drugs at the
same concentrations were equally efficacious with other
assay such as bactericidal activity. Thus, the results do
not necessarily prove actual intrinsic differences in the
inhibitory efficacy of these drugs.
Conclusions
Clarithromycin suppressed IL-13–induced periostin pro-
duction in human lung fibroblasts, in part through inhib-
ition of STAT6 phosphorylation. This suggests a novel
mechanism of the immunomodulatory effect of clarithro-
mycin in asthmatic airway inflammation and fibrosis.
Additional files
Additional file 1: Figure S1. Expression of IL-4Rα and IL-13Rα1 in MRC5
cells. (A) Cell surface expression of IL-4Rα and IL-13Rα1 was assessed by flow
cytometry. Mean fluorescent intensities (MFI) of the stained cells are shown.
(B) Expression of mRNA of the indicated genes was assessed by quantitative
RT-PCR. Fold changes over vehicle are shown. Black columns, clarithromycin
(CAM); gray columns, vehicle. Statistical analyses were performed using
Bonferroni’s multiple comparison test. P values of 0.05 or less were regarded
significant. NS, not significant; MFI, mean fluorescent intensity. (PPT 121 kb)
Additional file 2: Materials and Methods. (DOCX 21 kb)
Table 1 Representative genes that were increased more than
4-fold by IL-13 according to the global gene expression analysis
(see Figure 4.)
(A) Cluster Gene Symbol CAM effect
Extracellular PLXDC1 0.0342
Extracellular SLIT2 0.4594
Extracellular POSTN 0.4979
Extracellular WNT10B 0.4239
Plasma membrane CACNA1D 0.0807
Plasma membrane RTP1 0.1379
Plasma membrane SYT8 0.2078
Plasma membrane RALGPS1 0.2754
Plasma membrane APC 0.2138
Defense response CD40 0.0131
Defense response NOS2 0.3132
Defense response CD19 0.1667
Defense response IFNL1 0.0426
Defense response CXCL1 0.2197
(B) Cluster Gene Symbol CAM effect
Glycoprotein IL17RA 0.9564
Glycoprotein ST8SIA1 0.6773
Glycoprotein SPINT2 0.8788
Glycoprotein IL1RL1 0.7990
Glycoprotein SULF1 0.5449
Glycoprotein APLNR 1.0210
Glycoprotein HS3ST1 0.9854
Chemotaxis CCL26 1.2418
Chemotaxis IL6 0.8210
Chemotaxis PTGDR2 0.7217
Signal regulator SOCS1 1.1385
Signal regulator CISH 0.8930
(C) Cluster Gene Symbol IL-13 effect
Chemotaxis CCL26 35.6732
Glycoprotein HS3ST1 12.2410
Glycoprotein ST8SIA1 10.7933
Chemotaxis IL6 10.1221
Signal regulator CISH 8.9751
Chemotaxis PTGDR2 7.2666
Unassigned LINC00971 7.2156
Signal regulator SOCS1 6.3270
Glycoprotein IL17RA 5.9221
Extracellular SLIT2 5.7987
(D) Cluster Gene Symbol CAM effect
Plasma membrane SLC22A20 0.1237
Unassigned XLOC_006850 0.1403
Unassigned XLOC_014512 0.1420
Table 1 Representative genes that were increased more than
4-fold by IL-13 according to the global gene expression analysis
(see Figure 4.) (Continued)
Unassigned SPDYE8P 0.1491
Defense response CD19 0.1667
Unassigned LOC100129675 0.1696
Unassigned LOC102724783 0.1880
Plasma membrane SYT8 0.2078
Centriole SASS6 0.2079
Plasma membrane APC 0.2138
(A) Genes suppressed by 50% or more by clarithromycin. (B) Genes not affected by
clarithromycin. The clarithromycin (CAM) effect denotes the ratio of signal intensities
obtained by clarithromycin treatment compared with no treatment. (C) The ten
top-ranked ten genes induced by IL-13. (D) The ten top-ranked genes
downregulated by clarithromycin in the presence of IL-13. The clarithromycin
(CAM) effect denotes the ratio of signal intensities obtained by clarithromycin
treatment compared with no treatment. The IL-13 effect denotes the ratio of
signal intensities obtained by IL-13 stimulation compared with no stimulation
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Abbreviations
CAM: Clarithromycin; CD40: Cluster of differentiation antigen 40; CXCL1:
C-X-C motif chemokine ligand 1; ELISA: Enzyme-linked immunosorbent assay;
ERK: Extracellular signal-regulated kinase; EtOH: Ethanol; GAPDH: Glyceraldehyde-3-
phosphate dehydrogenase; GO: Gene ontology; IL-13: Interleukin-13; IL-
13α1: Interleukin-13 receptor α1; IL-4: Interleukin-4; IL-4α: Interleukin-4
receptor α; JAK: Janus kinase; NF-κB: Nuclear factor-kappa B; NOS2: Nitric oxide
synthase 2; PCR: Polymerase chain reaction; qPCR: Quantitative PCR; STAT6: Signal
transducer and activator of transcription 6; WST-8: Water-soluble tetrazolium salt 8
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